IMMIX BIOPHARMA INC (IMMX) Stock Price & Overview
NASDAQ:IMMX • US45258H1068
Current stock price
The current stock price of IMMX is 10.09 USD. Today IMMX is down by -2.51%. In the past month the price increased by 10.76%. In the past year, price increased by 439.57%.
IMMX Key Statistics
- Market Cap
- 534.871M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.89
- Dividend Yield
- N/A
IMMX Stock Performance
IMMX Stock Chart
IMMX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to IMMX. When comparing the yearly performance of all stocks, IMMX is one of the better performing stocks in the market, outperforming 98.99% of all stocks.
IMMX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMMX. No worries on liquidiy or solvency for IMMX as it has an excellent financial health rating, but there are worries on the profitability.
IMMX Earnings
IMMX Forecast & Estimates
10 analysts have analysed IMMX and the average price target is 18.61 USD. This implies a price increase of 84.49% is expected in the next year compared to the current price of 10.09.
IMMX Groups
Sector & Classification
IMMX Financial Highlights
Over the last trailing twelve months IMMX reported a non-GAAP Earnings per Share(EPS) of -0.89. The EPS decreased by -12.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.08% | ||
| ROE | -31.39% | ||
| Debt/Equity | 0 |
IMMX Ownership
IMMX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.74 | 360.314B | ||
| AMGN | AMGEN INC | 15.33 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.55 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.99 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.55 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.37 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IMMX
Company Profile
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 18 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The firm's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Company Info
IPO: 2021-12-16
IMMIX BIOPHARMA INC
11400 West Olympic Blvd., Suite 200
Los Angeles CALIFORNIA US
Employees: 20
Phone: 18889581084
IMMIX BIOPHARMA INC / IMMX FAQ
What does IMMX do?
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 18 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The firm's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
What is the current price of IMMX stock?
The current stock price of IMMX is 10.09 USD. The price decreased by -2.51% in the last trading session.
What is the dividend status of IMMIX BIOPHARMA INC?
IMMX does not pay a dividend.
How is the ChartMill rating for IMMIX BIOPHARMA INC?
IMMX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is IMMX stock listed?
IMMX stock is listed on the Nasdaq exchange.
What is the outstanding short interest for IMMIX BIOPHARMA INC?
The outstanding short interest for IMMIX BIOPHARMA INC (IMMX) is 7.61% of its float.